首页> 外文期刊>Neuro-Oncology >Sex-specific gene and pathway modeling of inherited glioma risk
【24h】

Sex-specific gene and pathway modeling of inherited glioma risk

机译:遗传性胶质瘤风险的性别特异性基因和途径建模

获取原文
获取原文并翻译 | 示例
           

摘要

Background To date, genome-wide association studies (GWAS) have identified 25 risk variants for glioma, explaining 30% of heritable risk. Most histologies occur with significantly higher incidence in males, and this difference is not explained by currently known risk factors. A previous GWAS identified sex-specific glioma risk variants, and this analysis aims to further elucidate risk variation by sex using gene- and pathway-based approaches.Methods Results from the Glioma International Case-Control Study were used as a testing set, and results from 3 GWAS were combined via meta-analysis and used as a validation set. Using summary statistics for nominally significant autosomal SNPs (P 0.01 in a previous meta-analysis) and nominally significant X-chromosome SNPs (P 0.01), 3 algorithms (Pascal, BimBam, and GATES) were used to generate gene scores, and Pascal was used to generate pathway scores. Results were considered statistically significant in the discovery set when P 3.3 x 10(-6) and in the validation set when P 0.001 in 2 of 3 algorithms.Results Twenty-five genes within 5 regions and 19 genes within 6 regions reached statistical significance in at least 2 of 3 algorithms in males and females, respectively. EGFR was significantly associated with all glioma and glioblastoma in males only and a female-specific association in TERT, all of which remained nominally significant after conditioning on known risk loci. There were nominal associations with the BioCarta telomeres pathway in both males and females.Conclusions These results provide additional evidence that there may be differences by sex in genetic risk for glioma. Additional analyses may further elucidate the biological processes through which this risk is conferred.
机译:背景技术迄今为止,全基因组关联研究(GWAS)已确定了25种神经胶质瘤的风险变体,解释了30%的遗传风险。大多数组织学发生在男性中的发生率显着更高,并且目前已知的危险因素无法解释这种差异。之前的GWAS曾鉴定出性别特异的神经胶质瘤风险变异体,该分析旨在通过基于基因和途径的方法进一步阐明性别的风险变异性。方法将Glioma国际病例对照研究的结果用作测试集,并得出结果通过荟萃分析将来自3个GWAS的数据进行合并,并用作验证集。使用名义上显着的常染色体SNP(在先前的荟萃分析中P <0.01)和名义上显着的X染色体SNP(P <0.01)的汇总统计数据,使用3种算法(Pascal,BimBam和GATES)生成基因评分,并且Pascal用于生成途径得分。在3个算法中的2个算法中,当发现P <3.3 x 10(-6)时发现结果具有统计学意义,而当发现P <0.001时验证结果具有统计学意义。结果5个区域中的25个基因和6个区域中的19个基因达到统计学在男性和女性的3种算法中,至少有2种具有显着性意义。 EGFR仅在男性中与所有神经胶质瘤和胶质母细胞瘤显着相关,而在TERT中女性与特异性相关,在已知风险基因座条件下,所有这些在名义上仍然显着。在男性和女性中,都有与BioCarta端粒途径相关的名义关联。结论这些结果提供了进一步的证据,表明神经胶质瘤的遗传风险可能存在性别差异。进一步的分析可以进一步阐明赋予该风险的生物学过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号